We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IceCure Secures China NMPA Approval for ProSense Cryoablation System
Read MoreHide Full Article
Key Takeaways
IceCure secured China NMPA approval for ProSense, enabling commercial marketing in the country.
ICCM's clearance expands its global revenue opportunity and supports broader international adoption.
IceCure can now focus on market adoption, distributor partnerships and higher procedure volumes.
IceCure Medical (ICCM - Free Report) recently secured regulatory approval from China's National Medical Products Administration (“NMPA”) for its ProSense cryoablation system and associated cryoprobes. The clearance marks a key milestone in the company's international expansion strategy and allows the technology to be commercially marketed in China.
The approval broadens IceCure's addressable market by opening access to one of the world's largest healthcare markets. While commercial execution and adoption will remain the next key factors to watch, the regulatory win strengthens the company's global commercialization footprint and creates a new avenue for potential long-term revenue growth.
Likely Trend of ICCM Stock Following the News
Following the announcement, shares of ICCM lost approximately 4% in yesterday’s after-market trading. Year to date, shares of the company have plunged 88.3% against the industry’s 1.9% growth. However, the S&P 500 has risen 10.9% in the same timeframe.
The NMPA approval is likely to strengthen IceCure's long-term growth prospects by adding China to the list of major markets where ProSense can be commercialized, expanding the company's global revenue opportunity. The clearance enhances ICCM's regulatory credibility, supports broader international adoption of its cryoablation technology and could pave the way for distributor partnerships and increased procedure volumes over time as the company executes its commercialization strategy in the region.
ICCM currently has a market capitalization of $7.2 million.
Image Source: Zacks Investment Research
More on the News
The NMPA granted Class III medical device approval for IceCure's ProSense system and its associated cryoprobes, enabling the company to market the platform in China in line with the approved registration. The clearance represents an important regulatory milestone for ICCM as it expands the number of markets where its flagship cryoablation technology is authorized for commercialization. Management noted that the approval reinforces the company's global regulatory standing and advances its efforts to expand patient access to minimally invasive tumor treatment options.
ProSense is IceCure's flagship liquid-nitrogen-based cryoablation system designed to destroy tumors by freezing them, offering a minimally invasive alternative to surgical tumor removal. The platform is used to treat both benign and cancerous tumors and is primarily focused on breast, kidney, bone and lung cancer applications. The procedure is performed through a relatively short intervention, making it an attractive treatment option in appropriate clinical settings.
The latest approval adds to ProSense's growing international regulatory footprint, with the system already cleared or approved for multiple indications across the United States, Europe and Asia. The expanded geographic reach is expected to support the company's commercialization efforts by increasing access to healthcare providers and patients across key global markets. As IceCure builds on this broader regulatory base, the focus is likely to shift toward driving market adoption and expanding the use of ProSense in approved indications.
Per a report by Verified Market Reports, the global cryoablation for cancer market size was valued at $3.5 billion in 2024 and is projected to register a CAGR of 6.1% from 2026 to 2033, reaching $5.8 billion by 2033.
The cryoablation market is experiencing strong growth, fueled by the rising incidence of cancer, an aging population and innovations in cryotherapy. A major driver of this expansion is the increasing adoption of cryoablation for smaller tumors, as it offers fewer side effects compared to traditional treatments.
Other News
Recently, IceCure Medical entered into an exclusive distribution agreement with Scovas Medical to commercialize its ProSense cryoablation system in the Netherlands for breast cancer and interventional oncology applications. The initial agreement is expected to support market development, physician education and broader clinical access in a market with strong interventional radiology expertise and growing demand for minimally invasive cancer treatments, potentially strengthening the company's commercial presence in Europe.
ICCM’s Zacks Rank & Key Picks
Currently, ICCM has a Zacks Rank #5 (Strong Sell).
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
IceCure Secures China NMPA Approval for ProSense Cryoablation System
Key Takeaways
IceCure Medical (ICCM - Free Report) recently secured regulatory approval from China's National Medical Products Administration (“NMPA”) for its ProSense cryoablation system and associated cryoprobes. The clearance marks a key milestone in the company's international expansion strategy and allows the technology to be commercially marketed in China.
The approval broadens IceCure's addressable market by opening access to one of the world's largest healthcare markets. While commercial execution and adoption will remain the next key factors to watch, the regulatory win strengthens the company's global commercialization footprint and creates a new avenue for potential long-term revenue growth.
Likely Trend of ICCM Stock Following the News
Following the announcement, shares of ICCM lost approximately 4% in yesterday’s after-market trading. Year to date, shares of the company have plunged 88.3% against the industry’s 1.9% growth. However, the S&P 500 has risen 10.9% in the same timeframe.
The NMPA approval is likely to strengthen IceCure's long-term growth prospects by adding China to the list of major markets where ProSense can be commercialized, expanding the company's global revenue opportunity. The clearance enhances ICCM's regulatory credibility, supports broader international adoption of its cryoablation technology and could pave the way for distributor partnerships and increased procedure volumes over time as the company executes its commercialization strategy in the region.
ICCM currently has a market capitalization of $7.2 million.
Image Source: Zacks Investment Research
More on the News
The NMPA granted Class III medical device approval for IceCure's ProSense system and its associated cryoprobes, enabling the company to market the platform in China in line with the approved registration. The clearance represents an important regulatory milestone for ICCM as it expands the number of markets where its flagship cryoablation technology is authorized for commercialization. Management noted that the approval reinforces the company's global regulatory standing and advances its efforts to expand patient access to minimally invasive tumor treatment options.
ProSense is IceCure's flagship liquid-nitrogen-based cryoablation system designed to destroy tumors by freezing them, offering a minimally invasive alternative to surgical tumor removal. The platform is used to treat both benign and cancerous tumors and is primarily focused on breast, kidney, bone and lung cancer applications. The procedure is performed through a relatively short intervention, making it an attractive treatment option in appropriate clinical settings.
The latest approval adds to ProSense's growing international regulatory footprint, with the system already cleared or approved for multiple indications across the United States, Europe and Asia. The expanded geographic reach is expected to support the company's commercialization efforts by increasing access to healthcare providers and patients across key global markets. As IceCure builds on this broader regulatory base, the focus is likely to shift toward driving market adoption and expanding the use of ProSense in approved indications.
IceCure Medical Ltd. Price
IceCure Medical Ltd. price | IceCure Medical Ltd. Quote
Industry Prospects Favoring the Market
Per a report by Verified Market Reports, the global cryoablation for cancer market size was valued at $3.5 billion in 2024 and is projected to register a CAGR of 6.1% from 2026 to 2033, reaching $5.8 billion by 2033.
The cryoablation market is experiencing strong growth, fueled by the rising incidence of cancer, an aging population and innovations in cryotherapy. A major driver of this expansion is the increasing adoption of cryoablation for smaller tumors, as it offers fewer side effects compared to traditional treatments.
Other News
Recently, IceCure Medical entered into an exclusive distribution agreement with Scovas Medical to commercialize its ProSense cryoablation system in the Netherlands for breast cancer and interventional oncology applications. The initial agreement is expected to support market development, physician education and broader clinical access in a market with strong interventional radiology expertise and growing demand for minimally invasive cancer treatments, potentially strengthening the company's commercial presence in Europe.
ICCM’s Zacks Rank & Key Picks
Currently, ICCM has a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.